- Home
- THAR vs RSLS Comparison
THAR vs RSLS Comparison
Compare THAR & RSLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- RSLS
- Stock Information
- Founded
- THAR 2017
- RSLS 2002
- Country
- THAR United States
- RSLS United States
- Employees
- THAR N/A
- RSLS N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- RSLS Medical/Dental Instruments
- Sector
- THAR Health Care
- RSLS Health Care
- Exchange
- THAR Nasdaq
- RSLS Nasdaq
- Market Cap
- THAR 2.8M
- RSLS 3.4M
- IPO Year
- THAR 2022
- RSLS 2007
- Fundamental
- Price
- THAR $2.13
- RSLS $4.70
- Analyst Decision
- THAR
- RSLS Hold
- Analyst Count
- THAR 0
- RSLS 1
- Target Price
- THAR N/A
- RSLS N/A
- AVG Volume (30 Days)
- THAR 232.7K
- RSLS 34.2K
- Earning Date
- THAR 11-07-2024
- RSLS 11-14-2024
- Dividend Yield
- THAR N/A
- RSLS N/A
- EPS Growth
- THAR N/A
- RSLS N/A
- EPS
- THAR N/A
- RSLS N/A
- Revenue
- THAR N/A
- RSLS $8,183,000.00
- Revenue This Year
- THAR N/A
- RSLS $17.47
- Revenue Next Year
- THAR N/A
- RSLS $20.00
- P/E Ratio
- THAR N/A
- RSLS N/A
- Revenue Growth
- THAR N/A
- RSLS N/A
- 52 Week Low
- THAR $1.84
- RSLS $4.09
- 52 Week High
- THAR $8.55
- RSLS $29.00
- Technical
- Relative Strength Index (RSI)
- THAR 46.63
- RSLS 39.12
- Support Level
- THAR $2.09
- RSLS $4.09
- Resistance Level
- THAR $2.27
- RSLS $4.89
- Average True Range (ATR)
- THAR 0.17
- RSLS 0.38
- MACD
- THAR -0.00
- RSLS -0.05
- Stochastic Oscillator
- THAR 34.04
- RSLS 32.97
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.